What is miDiagnostics?
miDiagnostics is at the forefront of developing advanced molecular diagnostic tests designed for screening, diagnosing, and monitoring a wide spectrum of health conditions. Leveraging a proprietary silicon chip and nanoFluidic Processor, the company's technology facilitates ultra-fast, cost-effective, and highly reliable testing. This innovation is poised to significantly enhance patient care by enabling rapid and accurate results, particularly in point-of-care settings. miDiagnostics aims to revolutionize the traditional diagnostics market by providing healthcare professionals with efficient and precise tools.
How much funding has miDiagnostics raised?
miDiagnostics has raised a total of $32M across 1 funding round:
Series D
$32M
Series D (2024): $32M with participation from Vmf Investment Group, Alychlo, and Thermo Fisher Scientific
Key Investors in miDiagnostics
Vmf Investment Group
Vmf Investment Group is a venture capital entity that operates within the private equity sector, likely focusing on strategic investments in companies with significant growth potential.
Alychlo
Alychlo is a family investment company founded by entrepreneur Marc Coucke, specializing in providing active support to growth-stage companies, emphasizing a human-centered approach to investment.
Thermo Fisher Scientific
Thermo Fisher Scientific is a global leader in serving science, providing analytical instruments, equipment, reagents, and consumables for research, diagnostics, and biotechnology.
What's next for miDiagnostics?
The recent major enterprise-level funding indicates miDiagnostics is likely in a growth or expansion phase, focusing on scaling its operations and market penetration. This capital infusion will probably be directed towards further research and development, expanding manufacturing capabilities, and broadening its commercial reach. The strategic nature of the investment suggests a strong belief in miDiagnostics' technology and its potential to disrupt the diagnostics landscape, potentially leading to new partnerships and market entries.
See full miDiagnostics company page
